Standardizing Drug Approval and Reimbursement Policies in the EU for Improved Myeloma Patient Care

2. EU Drug Approval and Reimbursement Policy Mait RaavaEstonian Myeloma Society Copenhagen, June 11th2016

3. What is the issue as we see it? • No standardized cost-benefit formula exists across the EU. • The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) refused to approve bortezomib in 2013 as front line therapy for patients who were transplantation eligible, but did it after European Medicine Agency approved bortezomib (based on HOVON-65 results) in 2013. • The Estonian reimbursement committee refused to approve bortezomib in first line for patient’s ineligible for transplantation in 2015 declaring that bortezomib and thalidomide research results are not comparable.

4. Myeloma patients overall survival • 2005 – 2009 medianOS in Estonia was 2,5 years* • 2006 – 2010 median OS at Mayo Clinic was 6,1 years** • “The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. • The improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.” * Innos K, Aareleid T. (2013). Vähielulemus Eestis 2005 – 2009. Eesti Arst, 92(8), 437-442 . ** Kumar, S. K. et al. (2014). Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 28(5), 1122-8. 6,1 2,5

5. Multiple myeloma treatment schemes in the 1. line in elderly (1) Thalidomide (MPT) or bortezomib (MPV) * Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-OncologievoorVolwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011 Aug 4;118(5):1239-47. ** San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.JClinOncol. 2013 Feb 1;31(4):448-55. *** Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014 Sep 18;124(12):1887-93. MPV*** PFS 32 m OS 63 m MPV** PFS 24 m OS 56,4 m MPT* PFS 20,3 m OS 39,3 m

6. Multiple myeloma treatment schemes in the 1. line in elderly (2) Thalidomide (MPT) or bortezomib (MPV)Theretrospectivecase-matchedstudy* * Morabito F, Bringhen S,Larocca A et al. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) inelderlynewlydiagnosedmultiplemyelomatients: A retrospectivecase-matchedstudy. Am J of Hematol. 2014 Apr; 89[4]: 355-362. MPV PFS 32,5 m OS 79,7 m MPT PFS 22,9 m OS 45,1 m

7. Why is the issue a problem for patients? • If the European Medicine Agency approves a new medicine, it is not available in all European Union countries because each country decides differently about cost-benefit, using different formulas and information to determine approval. • The assessment criteria used by each country is unclear and the data input for each country’s formula may or may not be based onscientific research. • This creates a patch-work of approvals across the EU and makes predicting the chance of success for a particular drugs approval difficult.

8. What is our proposed solution? • An assessment of a drug’s effectiveness from a single, scientific source that would be used as a universal measure across all EU countries. • A standard formula for determining cost-to-benefit for reimbursement, instead of the individual and varied formulas currently used. • Because of the availability of new drugs, myeloma patients in Eastern-European countries survive as long as in established European countries where new drugs are available already .

9. Why is our solution better for patients? • If the cost-benefit analysis is reliable and valid it is possible to achieve acceptable pricing from pharmaceutical companies and the new drug will be accessible. • Currently the situation exists where national reimbursement committees reject the proposals based on confused arguments (e.g. because of “incomparable” studies etc.) and the price negotiation suffers from poor information.

10. How do we see this solution unfolding? • Collect data of available first line treatments for transplantation eligible and ineligible patients, and overall survival rates in each European country. • Work with one another and our industry partners to engage politicians who have the authority to make changes happen and present them with our findings so that they support our position. • Once support has been established, create a decisive action plan that educates the public and policymakers on the issue to ensure legislation is enacted.

11. OurVision 2018 European Medicine Agency approves the new drug only if: • Drug’s effectiveness is proven by a common scientific body who's evaluation would be used as a benchmark across all EU countries. • A standard formula is used for determining cost-to-benefit for reimbursement, instead of the individual and varied formulas currently used. • Pharmaceutical company declares that it makes drug available in every EU country with the incremental cost (ICER) per QALY that doesn’t exceed per capita two GDP in every particular country.